Perspective Therapeutics (CATX) Accumulated Depreciation (2017 - 2026)

Perspective Therapeutics' Accumulated Depreciation history spans 14 years, with the latest figure at $7.3 million for Q1 2026.

  • On a quarterly basis, Accumulated Depreciation rose 98.59% to $7.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $7.3 million, a 98.59% increase, with the full-year FY2025 number at $6.2 million, up 109.59% from a year prior.
  • Accumulated Depreciation hit $7.3 million in Q1 2026 for Perspective Therapeutics, up from $6.2 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation for CATX hit a ceiling of $8.3 million in Q3 2023 and a floor of $15000.0 in Q4 2022.
  • Historically, Accumulated Depreciation has averaged $4.8 million across 5 years, with a median of $5.2 million in 2025.
  • Biggest five-year swings in Accumulated Depreciation: crashed 99.8% in 2022 and later skyrocketed 4360.0% in 2023.
  • Tracing CATX's Accumulated Depreciation over 5 years: stood at $15000.0 in 2022, then skyrocketed by 4360.0% to $669000.0 in 2023, then skyrocketed by 342.45% to $3.0 million in 2024, then soared by 109.59% to $6.2 million in 2025, then rose by 18.12% to $7.3 million in 2026.
  • Business Quant data shows Accumulated Depreciation for CATX at $7.3 million in Q1 2026, $6.2 million in Q4 2025, and $5.2 million in Q3 2025.